Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy

Drug Discovery Today

Volumn 20, Issue 5, 2015, Pages 609-617

  Austin, Christopher J D ^a   Rendina, Louis M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DIOXYGENASE; IMMUNOLOGIC FACTOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 2, HUMAN; KYNURENINE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; ENZYME ACTIVE SITE; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; DIOXYGENASES; DRUG DISCOVERY; HUMANS; IMMUNOLOGIC FACTORS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPTOPHAN; TRYPTOPHAN OXYGENASE;

EID: 84939977228     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.11.007     Document Type: Review

References (73)

1. D.M. Richard L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications Int. J. Tryptophan Res. 2 2009 45 60
2. G.W. Beadle Kynurenine as an intermediate in the formation of nicotinic acid from tryptophane by Neurospora Proc. Natl. Acad. Sci. U. S. A. 33 1947 155 158
3. Y. Chen, and G.J. Guillemin Kynurenine pathway metabolites in humans: disease and healthy States Int. J. Tryptophan Res. 2 2009 1 19
4. Y. Kotake, and T. Masayama Uber den Mechanismus der Kynurenin-bildung aus Tryptophan Hoppe-Seyler's Z. Physiol. Chem. 243 1937 237 244
5. M. Kanai Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice Mol. Brain 2 2009 8
6. L. Pilotte Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase Proc. Natl. Acad. Sci. U. S. A. 109 2012 2497 2502
7. C.L. Miller Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder Brain Res. 1073-1074 2006 25 37
8. S. Yamamoto, and O. Hayaishi Tryptophan pyrrolase of rabbit intestine, D- and L-tryptophan-cleaving enzyme or enzymes J. Biol. Chem. 242 1967 5260 5266
9. M.W. Taylor, and G.S. Feng Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism FASEB J. 5 1991 2516 2522
10. H.H. Hassanain Differential regulation of human indoleamine 2,3-dioxygenase gene expression by interferons-gamma and -alpha. Analysis of the regulatory region of the gene and identification of an interferon-gamma-inducible DNA-binding factor J. Biol. Chem. 268 1993 5077 5084
11. O. Hayaishi Indoleamine 2,3-dioxygenase: with special reference to the mechanism of interferon action Biken. J. 28 1985 39 49
12. S. Fujigaki Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism Eur. J. Immunol. 31 2001 2313 2318
13. T.A. Babcock, and J.M. Carlin Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferon-treated epithelial cells Cytokine 12 2000 588 594
14. J.B. Aitken The Fe-heme structure of met-indoleamine 2,3-dioxygenase-2 determined by X-ray absorption fine structure Biochem. Biophys. Res. Commun. 450 2014 25 29
15. H.J. Ball Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway Int. J. Biochem. Cell Biol. 41 2009 467 471
16. C.J. Austin Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2 Amino Acids 39 2010 565 578
17. R. Metz IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation Int. Immunol. 26 2014 357 367
18. R. Metz Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan Cancer Res. 67 2007 7082 7087
19. H.J. Yuasa Evolution of vertebrate indoleamine 2,3-dioxygenases J. Mol. Evol. 65 2007 705 714
20. D.H. Munn GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase Immunity 22 2005 633 642
21. F. Fallarino Tryptophan catabolism generates autoimmune-preventive regulatory T cells Transpl. Immunol. 17 2006 58 60
22. A.K. Manlapat Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells Eur. J. Immunol. 37 2007 1064 1071
23. P. Puccetti, and U. Grohmann IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappa B activation Nat. Rev. Immunol. 7 2007 817 823
24. L.K. Jasperson Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality Blood 111 2008 3257 3265
25. M.P. Heyes Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease Brain 115 1992 1249 1273
26. A. Bessede Aryl hydrocarbon receptor control of a disease tolerance defence pathway Nature 511 2014 184 190
27. C.A. Opitz An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Nature 478 2011 197 203
28. C.F. Vogel Aryl hydrocarbon receptor signaling mediates expression of indoleamine 2,3-dioxygenase Biochem. Biophys. Res. Commun. 375 2008 331 335
29. G.C. Prendergast Immune escape as a fundamental trait of cancer: focus on IDO Oncogene 27 2008 3889 3900
30. J.R. Brody Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival Cell Cycle 8 2009 1930 1934
31. G. Gerlini Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes J. Invest. Dermatol. 130 2010 898 901
32. A.J. Muller Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate Cancer Res. 70 2010 1845 1853
33. J. Yu Upregulated expression of indoleamine 2, 3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis Clin. Dev. Immunol. 2011 2011 469135
34. K. Sakurai Study of indoleamine 2,3-dioxygenase expression in patients with breast cancer Gan To Kagaku Ryoho 32 2005 1546 1549
35. C. Juhász Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies Nucl. Med. Biol. 39 2012 926 932
36. K. Sakurai Analysis of indoleamine 2, 3-dioxygenase expression in breast cancer patients with bone metastasis Gan To Kagaku Ryoho 39 2012 1776 1778
37. C. Uyttenhove Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase Nat. Med. 9 2003 1269 1274
38. R.B. Sorensen Spontaneous cytotoxic T-cell reactivity against indoleamine 2,3-dioxygenase-2 Cancer Res. 71 2011 2038 2044
39. H. Sugimoto Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase Proc. Natl. Acad. Sci. U. S. A. 103 2006 2611 2616
40. H.J. Ball Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice Gene 396 2007 203 213
41. D. Meininger Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors Biochim. Biophys. Acta 1814 2011 1947 1954
42. C. Lu Inhibitory substrate binding site of human indoleamine 2,3-dioxygenase J. Am. Chem. Soc. 131 2009 12866 12867
43. D. Batabyal, and S.R. Yeh Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase J. Am. Chem. Soc. 129 2007 15690 15701
44. D. Batabyal, and S.R. Yeh Substrate-protein interaction in human tryptophan dioxygenase: the critical role of H76 J. Am. Chem. Soc. 131 2009 3260 3270
45. L. Capece Substrate stereo-specificity in tryptophan dioxygenase and indoleamine 2,3-dioxygenase Proteins 78 2010 2961 2972
46. F. Forouhar Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase Proc. Natl. Acad. Sci. U. S. A. 104 2007 473 478
47. M. Salter The effects of a novel and selective inhibitor of tryptophan 2,3-dioxygenase on tryptophan and serotonin metabolism in the rat Biochem. Pharmacol. 49 1995 1435 1442
48. E. Dolusic Tryptophan 2,3-dioxygenase (TDO) inhibitors, 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators J. Med. Chem. 54 2011 5320 5334
49. J. Godin-Ethier Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives Clin. Cancer Res. 17 2011 6985 6991
50. S. Suzuki Expression of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase in early concepti Biochem. J. 355 2001 425 429
51. C.J. Austin Mouse and human indoleamine 2,3-dioxygenase display some distinct biochemical and structural properties Amino Acids 36 2009 99 106
52. D.Y. Hou Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses Cancer Res. 67 2007 792 801
53. C.A. Opitz The indoleamine-2, 3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells PLoS ONE 6 2011 e19823
54. L. Jia Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption Food Chem. Toxicol. 46 2008 203 211
55. H.J. Yuasa 1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan Comp. Biochem. Physiol. B 157 2010 10 15
56. Y. Kudo, and C. Boyd The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants J. Physiol. 531 2001 417 423
57. R. Metz IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: a novel IDO effector pathway targeted by D-1-methyl-tryptophan Oncoimmunology 1 2012 1460 1468
58. X. Liu Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity Blood 115 2010 3520 3530
59. H.K. Koblish Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors Mol. Cancer Ther. 9 2010 489 498
60. E.W. Yue Discovery of potent competitive inhibitors of indoleamine 2, 3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model J. Med. Chem. 52 2009 7364 7367
61. N. Seegers High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes J. BioMol. Screen. 19 2014 1266 1274
62. S.M. Bakmiwewa Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2 Bioorg. Med. Chem. Lett. 22 2012 7641 7646
63. S. Lob IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism Cancer Immunol. Immunother. 58 2009 153 157
64. M.S. Denison, and S.R. Nagy Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals Annu. Rev. Pharmacol. Toxicol. 43 2003 309 334
65. N. Eguchi Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives Arch. Biochem. Biophys. 232 1984 602 609
66. T. Herraiz, and C. Chaparro Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee Life Sci. 78 2006 795 802
67. A.M. Morin Norharman inhibition of [3H]diazepam binding in mouse brain Life Sci. 28 1981 2257 2263
68. K. Hayashi Interactions of norharman and harman with DNA Nucleic Acids Res. 4 1977 3679 3685
69. U.F. Rohrig Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors Eur. J. Med. Chem. 84C 2014 284 301
70. M.S. Denison, and S. Heath-Pagliuso The Ah receptor: a regulator of the biochemical and toxicological actions of structurally diverse chemicals Bull. Environ. Contam. Toxicol. 61 1998 557 568
71. W. Zhang Inhibition of cytochromes P450 by antifungal imidazole derivatives Drug Metab. Dispos. 30 2002 314 318
72. C.J. Austin The first indoleamine-2,3-dioxygenase-1 (IDO1) inhibitors containing carborane Dalton Trans. 43 2014 10719 10724
73. M. Platten Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion Cancer Res. 72 2012 5435 5440